<p>/PRNewswire/ -- Mabwell (688062.SH)，一家拥有完整产业链的创新驱动生物制药公司，宣布其针对 Nectin-4 的 ADC 9MW2821 与 toripalimab 联合用于尿路上皮癌的最新两项临床研究结果将于 2026 年美国临床肿瘤学会（ASCO）年会期间在美国芝加哥进行口头报告和海报展示，时间为 2026 年 5 月 29 日至 6 月 2 日（当地时间）。</p>
<p><strong>口头报告</strong></p>
<p>标题：Bulumtatug fuvedotin (BFv; 9MW2821) 与 toripalimab 联合治疗局部晚期或转移性尿路上皮癌（la/mUC）患者的后续结果：来自 1b/2 期研究的结果。</p>
<p>发表摘要编号：4518</p>
<p>报告人：盛西南教授，主任医师，博士生导师，北京癌症医院泌尿肿瘤科</p>
<p>会议日期和时间：2026 年 6 月 1 日上午 8:00-9:30 CDT</p>
<p><strong>海报展示</strong></p>
<p>标题：Bulumtatug fuvedotin (BFv; 9MW2821) 与 toripalimab 联合治疗肌肉侵袭性膀胱癌（MIBC）围手术期患者的结果：来自 2 期研究 A 组的结果。</p>
<p>发表摘要编号：4609</p>
<p>主要研究者：刘卓伟教授，主任医师，苏州大学癌症中心泌尿科</p>
<p>会议日期和时间：2026 年 5 月 31 日上午 9:00-12:00 CDT</p>
<p>关于 Mabwell</p>
<p>Mabwell (688062.SH) 是一家创新驱动的生物制药公司，具备覆盖整个制药价值链的能力。公司致力于提供更有效和可及的治疗方案，以满足全球医疗需求，重点关注肿瘤学和与衰老相关的疾病。Mabwell 的使命是 “探索生命，造福健康”，愿景是 “创新，从想法到现实”。更多信息，请访问 www.mabwell.com/en。</p>
<p>前瞻性声明</p>
<p>本新闻稿包含前瞻性声明，包括但不限于我们产品候选者的潜在安全性、有效性、监管审查或批准及商业成功，以及与公司产品开发、临床研究、临床和监管里程碑及时间表、市场机会、竞争地位、可能或假设的未来运营结果、商业策略、潜在增长机会及其他预测性陈述相关的内容。“前瞻性声明” 是指那些不是历史事实的陈述，涉及多种风险和不确定性，可能导致实际结果与前瞻性声明中表达或暗示的未来结果存在重大差异。这些陈述可以通过使用前瞻性表达来识别，包括但不限于 “期望”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜在”、“预测”、“项目”、“应该”、“会” 等类似表达及其否定形式。</p>
<p>前瞻性声明基于公司当前的期望和假设。前瞻性声明受到多种风险、不确定性和其他因素的影响，其中许多超出公司的控制，包括但不限于：环境；政治；经济；社会；立法；我们对产品候选者的依赖，其中大多数仍处于临床前或不同阶段的临床开发中；我们对第三方供应商的依赖，如合同研究组织和合同制造组织；临床测试中固有的不确定性；我们完成产品候选者所需临床试验并获得监管机构批准的能力；我们保护知识产权的能力；任何高管或关键人员的离职。如果这些风险或不确定性之一或多个恶化，或任何假设不正确，实际结果可能与所述结果严重不一致。</p>
<p>公司提醒所有人不要对任何此类前瞻性声明过度依赖，这些声明仅在本新闻稿发布之日有效。公司不承担任何义务，除非法律和适用证券监管机构的规则明确要求，公开更新或修订任何此类声明，以反映任何期望或事件、条件或情况的变化，或可能影响实际结果与前瞻性声明中所述结果的可能性。所有前瞻性描述、数字和假设在本新闻稿中均适用于本声明。</p>
<p>来源：Mabwell</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9Q040MTg1NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMwMjQ3UFJfTkVXU19VU1BSX19fX19DTjQxODU0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9Q040MTg1NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMwMjQ3UFJfTkVXU19VU1BSX19fX19DTjQxODU0"/></p>

君实生物-U

君实生物

纽交所高增长板生物技术指数 ETF - First Trust

<p>Mabwell 是一家生物制药公司，将在 2026 年芝加哥 ASCO 年会上展示其 ADC 9MW2821 与托瑞帕利单抗联合用于尿路上皮癌的临床数据。口头报告将涵盖 1b/2 期研究的后续结果，而海报展示将讨论针对肌肉侵袭性膀胱癌的 2 期研究结果。该活动定于 2026 年 5 月 29 日至 6 月 2 日举行，具体会议安排在 5 月 31 日和 6 月 1 日</p>

<p>, /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from May 29 to June 2, 2026 (local time), as an oral presentation and a poster presentation, respectively.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Mabwell (688062.SH)，一家拥有完整产业链的创新驱动生物制药公司，宣布其针对 Nectin-4 的 ADC 9MW2821 与 toripalimab 联合用于尿路上皮癌的最新两项临床研究结果将于 2026 年美国临床肿瘤学会（ASCO）年会期间在美国芝加哥进行口头报告和海报展示，时间为 2026 年 5 月 29 日至 6 月 2 日（当地时间）。</p>
</div><p><strong>Oral Presentation</strong></p>
<div class="lb-trans"><p><strong>口头报告</strong></p>
</div><p>Title: Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.</p>
<div class="lb-trans"><p>标题：Bulumtatug fuvedotin (BFv; 9MW2821) 与 toripalimab 联合治疗局部晚期或转移性尿路上皮癌（la/mUC）患者的后续结果：来自 1b/2 期研究的结果。</p>
</div><p>Abstract Number for Publication: 4518</p>
<div class="lb-trans"><p>发表摘要编号：4518</p>
</div><p>Presenter: Prof. Sheng Xinan, Chief Physician, doctoral supervisor, Dept. of Urologic Oncology (Beijing Cancer Hospital)</p>
<div class="lb-trans"><p>报告人：盛西南教授，主任医师，博士生导师，北京癌症医院泌尿肿瘤科</p>
</div><p>Session Date and Time: 6/1/2026 8:00AM-9:30AM CDT</p>
<div class="lb-trans"><p>会议日期和时间：2026 年 6 月 1 日上午 8:00-9:30 CDT</p>
</div><p><strong>Poster Presentation</strong></p>
<div class="lb-trans"><p><strong>海报展示</strong></p>
</div><p>Title: Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.</p>
<div class="lb-trans"><p>标题：Bulumtatug fuvedotin (BFv; 9MW2821) 与 toripalimab 联合治疗肌肉侵袭性膀胱癌（MIBC）围手术期患者的结果：来自 2 期研究 A 组的结果。</p>
</div><p>Abstract Number for Publication: 4609</p>
<div class="lb-trans"><p>发表摘要编号：4609</p>
</div><p>Principal Investigator: Prof. Liu Zhuowei, Chief Physician, Dept. of Urology (Sun Yat-sem University Cancer Center)</p>
<div class="lb-trans"><p>主要研究者：刘卓伟教授，主任医师，苏州大学癌症中心泌尿科</p>
</div><p>Session Date and Time: 5/31/2026 9:00AM-12:00PM CDT</p>
<div class="lb-trans"><p>会议日期和时间：2026 年 5 月 31 日上午 9:00-12:00 CDT</p>
</div><p>About Mabwell</p>
<div class="lb-trans"><p>关于 Mabwell</p>
</div><p>Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell's mission is &#34;Explore Life, Benefit Health&#34; and its vision is &#34;Innovation, from Ideas to Reality.&#34; For more information, please visit www.mabwell.com/en.</p>
<div class="lb-trans"><p>Mabwell (688062.SH) 是一家创新驱动的生物制药公司，具备覆盖整个制药价值链的能力。公司致力于提供更有效和可及的治疗方案，以满足全球医疗需求，重点关注肿瘤学和与衰老相关的疾病。Mabwell 的使命是 “探索生命，造福健康”，愿景是 “创新，从想法到现实”。更多信息，请访问 www.mabwell.com/en。</p>
</div><p>Forward-Looking Statements</p>
<div class="lb-trans"><p>前瞻性声明</p>
</div><p>This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. &#34;Forward-looking statements&#34; are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#34;expect,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;would,&#34; and similar expressions and the negatives of those terms.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括但不限于我们产品候选者的潜在安全性、有效性、监管审查或批准及商业成功，以及与公司产品开发、临床研究、临床和监管里程碑及时间表、市场机会、竞争地位、可能或假设的未来运营结果、商业策略、潜在增长机会及其他预测性陈述相关的内容。“前瞻性声明” 是指那些不是历史事实的陈述，涉及多种风险和不确定性，可能导致实际结果与前瞻性声明中表达或暗示的未来结果存在重大差异。这些陈述可以通过使用前瞻性表达来识别，包括但不限于 “期望”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜在”、“预测”、“项目”、“应该”、“会” 等类似表达及其否定形式。</p>
</div><p>Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.</p>
<div class="lb-trans"><p>前瞻性声明基于公司当前的期望和假设。前瞻性声明受到多种风险、不确定性和其他因素的影响，其中许多超出公司的控制，包括但不限于：环境；政治；经济；社会；立法；我们对产品候选者的依赖，其中大多数仍处于临床前或不同阶段的临床开发中；我们对第三方供应商的依赖，如合同研究组织和合同制造组织；临床测试中固有的不确定性；我们完成产品候选者所需临床试验并获得监管机构批准的能力；我们保护知识产权的能力；任何高管或关键人员的离职。如果这些风险或不确定性之一或多个恶化，或任何假设不正确，实际结果可能与所述结果严重不一致。</p>
</div><p>The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.</p>
<div class="lb-trans"><p>公司提醒所有人不要对任何此类前瞻性声明过度依赖，这些声明仅在本新闻稿发布之日有效。公司不承担任何义务，除非法律和适用证券监管机构的规则明确要求，公开更新或修订任何此类声明，以反映任何期望或事件、条件或情况的变化，或可能影响实际结果与前瞻性声明中所述结果的可能性。所有前瞻性描述、数字和假设在本新闻稿中均适用于本声明。</p>
</div><p>SOURCE Mabwell</p>
<div class="lb-trans"><p>来源：Mabwell</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIzJk5ld3NJdGVtSWQ9Q040MTg1NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjMwMjQ3UFJfTkVXU19VU1BSX19fX19DTjQxODU0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN41854&amp;Transmission_Id=202604230247PR_NEWS_USPR_____CN41854&amp;DateId=20260423"/></p>

02:47 ET2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

2026 年美国临床肿瘤学会年会 | Mabwell 将在口头报告和海报展示中发布 9MW2821 联合特瑞普利单抗治疗尿路上皮癌的最新临床数据